We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Julie
Kitcheman
medjki@leeds.ac.uk
Dr
Julia
Scarisbrick
julia.scarisbrick@uhb.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cancers have different features or characteristics that make each person’s tumour unique. So people with cancer should not necessarily all be treated in the same way. Because there is still a lot of missing information about tumour characteristics, especially for rare cancers, the treatment opportunities and treatments that can be tailored to each person (personalised treatment) are limited.
This program aims to better understand the tumour characteristics of people diagnosed with a primary rare cancer. Participant's data and biological samples (such as tumour and blood samples) will be collected and analysed. The samples and information will be used to find tumour characteristics or changes to support translational and biomarker research that might:
- explain how cancer develops or progresses
- show how people respond to current or new treatments
- provide doctors with knowledge that may become relevant to the participant or help people with cancer in the future
- help doctors to understand which treatments may be helpful to participants. This will hopefully enable participants to be offered access to drugs/treatments that specifically target the characteristics of their tumour, in particular within clinical trials. This matching or 'personalising of treatment' aims to improve outcomes for individual patients. These trials may be already ongoing or planned for the future.
The program will take place in the UK and in several countries across Europe. Approximately 500 patients will be invited to participate in this program every year.This program will last as long as it is scientifically and ethically relevant and practically possible.
The program is developed and run by European Organisation for Research and Treatment of Cancer (EORTC), an independent, non-profit clinical research organisation based in Brussels, Belgium.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
♦ Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the program.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Julia
Scarisbrick
julia.scarisbrick@uhb.nhs.uk
Julie
Kitcheman
medjki@leeds.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by European Organisation for Research and Treatment of Cancer and funded by European Organisation for Research and Treatment of Cancer .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 33914
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
